Drugs /

alectinib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
alectinib
Trade Name(s):
Alecensa
NCI Definition [1]:
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for alectinib

Alectinib has been investigated in 18 clinical trials, of which 16 are open and 2 are closed. Of the trials investigating alectinib, 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open).

ALK Fusion, ALK Mutation, and ALK Alternative Transcription Site are the most frequent biomarker inclusion criteria for alectinib clinical trials.

Non-small cell lung carcinoma, malignant solid tumor, and lung adenocarcinoma are the most common diseases being investigated in alectinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Alectinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Alectinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating alectinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ch5424802, ro5424802, af802, 5h-benzo(b)carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, af-802, alectinib (substance), rg7853, alk inhibitor ch5424802, anaplastic lymphoma kinase inhibitor ch5424802, 1256580-46-7, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile, unii-lij4ct1z3y, Alecensa, alectinib, alectinib
Drug Categories [2]:
ALK inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
ALK, RET
NCIT ID [1]:
C101790
SNOMED ID [1]:
R-FF7EE

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.